Rating Change
Stephens & Co. reiterated its Overweight rating on 10x Genomics, Inc. (NASDAQ:TXG) on August 12, 2026.
reiterateNASDAQ:TXG
Stephens & Co. Reiterates Overweight Rating on 10x Genomics, Inc. (TXG)
Stephens & Co. reiterated its Overweight rating on 10x Genomics, Inc.
At publication ·
What changed
10x Genomics, Inc. (NASDAQ:TXG) · reiterate
- Firm
- Stephens & Co.
- Rating
- Overweight to Overweight
- Price at event
- $57.75
- Market capitalization
- $2.0B
At a glance
Key takeaways
- Stephens & Co. reiterated an Overweight rating on 10x Genomics (TXG) on August 12, 2026, with the stock trading at $57.75 and a market capitalization of $2.0 billion.
Market Context
10x Genomics, Inc. operates in the Healthcare sector. The stock currently trades at $57.75 with a market capitalization of $2.0B.
Analyst coverage from Stephens & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for 10x Genomics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for 10x Genomics, Inc.
Among the 10 most recent ratings: 3 Buy, 7 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 12, 2026 | Stephens & Co. | Overweight | N/A |
| Aug 10, 2026 | Canaccord Genuity | Buy | N/A |
| Aug 10, 2026 | Piper Sandler | Neutral | N/A |
| Aug 07, 2026 | Citigroup | Neutral | N/A |
| Aug 07, 2026 | Morgan Stanley | Equal-Weight | N/A |
Related Tools: Analyst Ratings Dashboard | View TXG Stock Page
Frequently Asked Questions
What does the Overweight rating mean for TXG?
A rating of Overweight from Stephens & Co. reflects the analyst's outlook on 10x Genomics, Inc. (NASDAQ:TXG). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the TXG forecast page.